Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
about
Molecular testing to optimize therapeutic decision making in advanced colorectal cancerBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerNew therapeutic strategies for BRAF mutant colorectal cancersTreatment Individualization in Colorectal CancerMolecular profiling in the treatment of colorectal cancer: focus on regorafenibToward a Molecular Classification of Colorectal Cancer: The Role of BRAFTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerCIViC databaseRegorafenib in metastatic colorectal cancer.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS StatusExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersDetection of circulating tumor DNA in early- and late-stage human malignanciesDNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancerAnalyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients.Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer.Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.A framework for genomic biomarker actionability and its use in clinical decision makingEffectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.Can we accurately report PTEN status in advanced colorectal cancer?Expanded RAS: refining the patient populationExternal quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials.Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyBRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study.In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.RAS testing in metastatic colorectal cancer: advances in EuropeNovel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal CancerMicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection.
P2860
Q26749012-E3BFCC7D-2009-46D4-8EA8-3A1E364762B3Q26766535-6F5AABB7-C20E-4D66-B40E-384BE3C3B2A0Q26771952-8079C630-6884-4CE9-B222-B4E4ADAB2C87Q26772277-9C957E70-AA97-4FE5-8F29-1DB2402E453BQ26776215-49339297-4BC5-42F1-8E86-592B8EDB3E87Q26778296-D061E1C3-DFA4-48B8-9E3C-732D3D0890E6Q26827212-B7F617AA-70C9-455B-A3EA-99B96560912FQ27026489-3541B8DC-1CEA-4959-BB7C-4DE4582107D4Q27027648-7F2A68F2-6AD5-4CE5-985A-C50693F38B9CQ27612411-CC5EB72A-D4E9-45F3-9737-7D5281055F97Q27852864-AEF1C0FD-DCBA-48E0-8907-3C0148A3FD18Q27852988-0125FC58-9D91-4E4B-91DE-6113E6623096Q28082816-7AA253C3-686F-4B4C-893A-284C6A260B96Q28087333-692951D0-D80D-49B8-9ECB-333CC82BF2D2Q29615778-20A14FF7-7B3C-459B-B543-FFEB68344DD0Q33679684-C40C51A7-A7EC-4DF2-9A96-9045E9375977Q33732199-29569538-C2D8-4E24-BE37-6515996DED52Q33947862-868D57D1-5D33-4526-AFDC-32F62EB6DB56Q34038277-0956B44E-ECF2-4B15-8421-4DC783E45B0FQ34227451-93D92DA7-D9B2-45C5-8466-E5A44B638881Q34371471-AFFCBCE7-7BA2-4791-8272-E0C8D2165877Q34482529-ABB8289A-6C3F-48C7-B5AB-FC520AC866BDQ34528276-48E00291-0C1D-40DA-88B2-6F1EE66A5BBAQ34560270-1676A535-8574-421A-9CED-27AB9F32B8AEQ34781122-109A615E-553B-4CF9-AB77-61FA288EB4DCQ35067570-DE1C362B-A8F6-4BFE-A515-46A895CE9D71Q35101357-2CE8A03F-6864-4FF7-84E4-E77D5B039D1AQ35102475-E5B386F0-95FB-4954-91F1-0A7D93671263Q35151110-16471389-0049-4777-9D54-DD1EBFCD25A2Q35211367-F4BF9A27-485A-4268-A97D-C5E237825355Q35587176-5D6CD18E-5625-4549-A4A0-7C9982D7B4E1Q36028658-D57DD943-1DEA-4850-A9FC-153C30CCE62AQ36086837-7B0D9230-C060-41E4-904B-F5BADC027E51Q36201032-DAD98209-27B7-455F-83B1-06D42C07BE57Q36232353-DFEA43DF-53A3-4A13-B48A-B156CED53E52Q36310845-32DF17BE-9669-4AD6-8A49-400438582DC1Q36472959-2E108AFF-67CA-47F3-9D5C-CD4885F3246CQ36795904-A9497289-716B-4418-84A9-848A083FAA17Q36932799-F41731B3-61F4-4442-AAFC-0FF9D28B1BE9Q36963070-6EF45447-35FC-48E9-A5D1-915F21F2171C
P2860
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Massively parallel tumor multi ...... metastatic colorectal cancer.
@ast
Massively parallel tumor multi ...... metastatic colorectal cancer.
@en
Massively parallel tumor multi ...... metastatic colorectal cancer.
@nl
type
label
Massively parallel tumor multi ...... metastatic colorectal cancer.
@ast
Massively parallel tumor multi ...... metastatic colorectal cancer.
@en
Massively parallel tumor multi ...... metastatic colorectal cancer.
@nl
prefLabel
Massively parallel tumor multi ...... metastatic colorectal cancer.
@ast
Massively parallel tumor multi ...... metastatic colorectal cancer.
@en
Massively parallel tumor multi ...... metastatic colorectal cancer.
@nl
P2093
P50
P3181
P1476
Massively parallel tumor multi ...... metastatic colorectal cancer.
@en
P2093
Alex Parker
David Reese
Jeffrey Wiezorek
Jing Huang
Kelly S Oliner
Marc Peeters
Scott D Patterson
Thierry André
Yves Humblet
P304
P3181
P356
10.1158/1078-0432.CCR-12-1913
P407
P577
2013-04-01T00:00:00Z